Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Deloitte
Queensland Health
Mallinckrodt
Medtronic
Chubb
Covington
Express Scripts
QuintilesIMS

Generated: April 21, 2018

DrugPatentWatch Database Preview

INTEGRILIN Drug Profile

« Back to Dashboard

When do Integrilin patents expire, and what generic alternatives are available?

Integrilin is a drug marketed by Schering and is included in one NDA.

The generic ingredient in INTEGRILIN is eptifibatide. There are fifteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.
Drug patent expirations by year for INTEGRILIN
Pharmacology for INTEGRILIN
Synonyms for INTEGRILIN
[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
[22-Carbamoyl-14-(4-guanidino-butyl)-5-(1H-indol-3-ylmethyl)-4,7,10,13,16,24-hexaoxo-docosahydro-19,20-dithia-3a,6,9,12,15,23-hexaaza-cyclopentacyclotricosen-8-yl]-acetic acid (C68-22, eptifibatide)
148031-34-9
157630-07-4
17-yl)acetic acid
188627-80-7
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid
2-[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
2-[(3R,11S,17S,20S,25aS)-3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-[(1H-indol-3-yl)methyl]-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
31E349
ABP000579
AC1L9MDI
AKOS015895205
AKOS025147403
BC657177
BDBM50092098
C-23554
C35H49N11O9S2
C68-22
CAS-188627-80-7
CC-27500
CHEBI:291902
CHEMBL1174
CS-2925
CZKPOZZJODAYPZ-LROMGURASA-N
D09ZIO
DSSTox_CID_26673
DSSTox_GSID_46673
DSSTox_RID_81810
DTXSID7046673
eftifibatide
Eptifibatide
Eptifibatide [INN:BAN]
Eptifibatide Accord (generic)
Eptifibatide Acetate
Eptifibatide(Integrilin)/
GTPL6585
HS-2011
HSDB 8313
HY-B0686
Integrelin
Integrilin (TN)
Intrifiban
L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide
L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-|A-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1 inverted exclamation marku6)-disulfide
L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide
LS-173318
MCULE-5698614065
MolPort-006-069-141
N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
NA8320J834
NCGC00167505-01
NCGC00263524-01
S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]
SB-1
Sch-60936
SCHEMBL15781
Tox21_112503
Tox21_112503_1
UNII-NA8320J834
V1343
Z2241982440
ZINC85536935

US Patents and Regulatory Information for INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for INTEGRILIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 0.75 mg/mL, 100 mL vial ➤ Subscribe 2009-06-05
➤ Subscribe Injection 2 mg/mL, 100 mL vial ➤ Subscribe 2008-12-18
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2008-09-30

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Dow
Daiichi Sankyo
Deloitte
Colorcon
Teva
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.